Oncolytics Non Currrent Assets Other vs Cash Analysis

ONC Stock

CAD 1.33 0.04 2.92%

Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Non Currrent Assets Other and its Cash accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

Non Currrent Assets Other vs Cash

Non Currrent Assets Other vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Non Currrent Assets Other account and Cash. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Oncolytics Biotech's Non Currrent Assets Other and Cash is 0.14. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Cash in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Non Currrent Assets Other and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Oncolytics Biotech are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Non Currrent Assets Other i.e., Oncolytics Biotech's Non Currrent Assets Other and Cash go up and down completely randomly.

Correlation Coefficient

0.14

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Cash

Cash refers to the most liquid asset of Oncolytics Biotech, which is listed under current asset account on Oncolytics Biotech balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Oncolytics Biotech customers. The amounts must be unrestricted with restricted cash listed in a different Oncolytics Biotech account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is very stable compared to the past year. As of the 23rd of November 2024, Enterprise Value is likely to grow to about 118 M, while Tax Provision is likely to drop about 82.9 K.

	2021	2022	2023	2024 (projected)
Net Interest Income	98.6K	528K	1.3M	1.4M
Interest Income	19.9K	528K	1.3M	1.8M

Net Interest Income Interest Income

Oncolytics Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Non Currrent Assets Other	Short Term Investments	Short Term Debt	Other Assets	Other Current Liab	Common Stock
Total Assets		0.3	0.01	0.9	0.74	-0.84	-0.62	-0.1	0.84	-0.13	0.98	-0.15	0.7	0.46	0.73	0.67	0.32	0.65	1.0	-0.48	0.45	-0.06	-0.49	-0.03	0.06	0.65
Short Long Term Debt Total	0.3		0.37	0.24	0.58	-0.38	-0.29	0.42	0.49	-0.7	0.33	0.23	-0.12	-0.03	-0.1	0.36	0.32	0.05	0.36	-0.72	0.24	-0.5	-0.67	-0.74	-0.14	0.19
Total Current Liabilities	0.01	0.37		-0.3	0.29	0.01	-0.15	0.55	0.0	-0.39	-0.03	0.34	-0.11	0.09	-0.03	0.2	0.71	0.11	0.03	-0.42	0.23	-0.15	-0.41	-0.32	0.61	-0.01
Total Stockholder Equity	0.9	0.24	-0.3		0.51	-0.8	-0.33	-0.04	0.82	-0.04	0.94	-0.33	0.48	0.12	0.47	0.38	-0.1	0.41	0.9	-0.3	0.24	-0.15	-0.25	-0.03	-0.21	0.42
Property Plant And Equipment Net	0.74	0.58	0.29	0.51		-0.6	-0.75	-0.18	0.64	-0.23	0.7	0.04	0.59	0.59	0.62	0.77	0.64	0.63	0.76	-0.61	0.69	-0.05	-0.63	-0.29	0.18	0.77
Net Debt	-0.84	-0.38	0.01	-0.8	-0.6		0.43	0.04	-0.97	0.36	-0.87	0.25	-0.49	-0.27	-0.5	-0.47	-0.13	-0.62	-0.85	0.44	-0.08	0.28	0.42	-0.04	-0.04	-0.39
Retained Earnings	-0.62	-0.29	-0.15	-0.33	-0.75	0.43		0.35	-0.37	0.35	-0.55	-0.11	-0.84	-0.81	-0.84	-0.99	-0.6	-0.8	-0.62	0.7	-0.42	-0.05	0.79	0.01	-0.02	-0.93
Accounts Payable	-0.1	0.42	0.55	-0.04	-0.18	0.04	0.35		0.01	-0.47	-0.02	0.04	-0.55	-0.62	-0.54	-0.25	-0.05	-0.35	-0.06	-0.33	-0.23	-0.5	-0.19	-0.48	-0.07	-0.53
Cash	0.84	0.49	0.0	0.82	0.64	-0.97	-0.37	0.01		-0.34	0.87	-0.22	0.38	0.21	0.41	0.42	0.17	0.49	0.86	-0.43	0.14	-0.24	-0.4	-0.1	0.04	0.39
Non Current Assets Total	-0.13	-0.7	-0.39	-0.04	-0.23	0.36	0.35	-0.47	-0.34		-0.18	-0.14	0.07	0.05	0.08	-0.39	-0.19	-0.19	-0.18	0.84	0.35	0.48	0.78	0.45	0.2	-0.07
Cash And Short Term Investments	0.98	0.33	-0.03	0.94	0.7	-0.87	-0.55	-0.02	0.87	-0.18		-0.29	0.62	0.34	0.63	0.61	0.21	0.6	0.99	-0.49	0.35	-0.13	-0.47	-0.06	-0.02	0.57
Net Receivables	-0.15	0.23	0.34	-0.33	0.04	0.25	-0.11	0.04	-0.22	-0.14	-0.29		-0.1	0.24	0.03	0.13	0.43	-0.12	-0.14	-0.13	0.18	0.09	-0.28	-0.24	0.22	0.08
Common Stock Shares Outstanding	0.7	-0.12	-0.11	0.48	0.59	-0.49	-0.84	-0.55	0.38	0.07	0.62	-0.1		0.81	0.98	0.82	0.39	0.89	0.67	-0.31	0.42	0.13	-0.4	0.43	0.1	0.86
Non Current Liabilities Total	0.46	-0.03	0.09	0.12	0.59	-0.27	-0.81	-0.62	0.21	0.05	0.34	0.24	0.81		0.87	0.79	0.71	0.68	0.44	-0.28	0.51	0.41	-0.45	0.21	0.32	0.83
Other Current Assets	0.73	-0.1	-0.03	0.47	0.62	-0.5	-0.84	-0.54	0.41	0.08	0.63	0.03	0.98	0.87		0.83	0.5	0.85	0.7	-0.31	0.47	0.24	-0.44	0.36	0.21	0.86
Other Stockholder Equity	0.67	0.36	0.2	0.38	0.77	-0.47	-0.99	-0.25	0.42	-0.39	0.61	0.13	0.82	0.79	0.83		0.64	0.79	0.68	-0.75	0.43	0.02	-0.84	-0.06	0.03	0.91
Total Liab	0.32	0.32	0.71	-0.1	0.64	-0.13	-0.6	-0.05	0.17	-0.19	0.21	0.43	0.39	0.71	0.5	0.64		0.4	0.33	-0.45	0.56	0.25	-0.56	-0.21	0.61	0.59
Property Plant And Equipment Gross	0.65	0.05	0.11	0.41	0.63	-0.62	-0.8	-0.35	0.49	-0.19	0.6	-0.12	0.89	0.68	0.85	0.79	0.4		0.63	-0.44	0.25	-0.2	-0.49	0.44	0.18	0.72
Total Current Assets	1.0	0.36	0.03	0.9	0.76	-0.85	-0.62	-0.06	0.86	-0.18	0.99	-0.14	0.67	0.44	0.7	0.68	0.33	0.63		-0.52	0.43	-0.08	-0.53	-0.08	0.05	0.65
Intangible Assets	-0.48	-0.72	-0.42	-0.3	-0.61	0.44	0.7	-0.33	-0.43	0.84	-0.49	-0.13	-0.31	-0.28	-0.31	-0.75	-0.45	-0.44	-0.52		-0.13	0.32	0.97	0.51	0.16	-0.48
Non Currrent Assets Other	0.45	0.24	0.23	0.24	0.69	-0.08	-0.42	-0.23	0.14	0.35	0.35	0.18	0.42	0.51	0.47	0.43	0.56	0.25	0.43	-0.13		0.2	-0.19	-0.25	0.33	0.54
Short Term Investments	-0.06	-0.5	-0.15	-0.15	-0.05	0.28	-0.05	-0.5	-0.24	0.48	-0.13	0.09	0.13	0.41	0.24	0.02	0.25	-0.2	-0.08	0.32	0.2		0.2	0.0	0.22	0.22
Short Term Debt	-0.49	-0.67	-0.41	-0.25	-0.63	0.42	0.79	-0.19	-0.4	0.78	-0.47	-0.28	-0.4	-0.45	-0.44	-0.84	-0.56	-0.49	-0.53	0.97	-0.19	0.2		0.45	0.1	-0.59
Other Assets	-0.03	-0.74	-0.32	-0.03	-0.29	-0.04	0.01	-0.48	-0.1	0.45	-0.06	-0.24	0.43	0.21	0.36	-0.06	-0.21	0.44	-0.08	0.51	-0.25	0.0	0.45		0.19	0.06
Other Current Liab	0.06	-0.14	0.61	-0.21	0.18	-0.04	-0.02	-0.07	0.04	0.2	-0.02	0.22	0.1	0.32	0.21	0.03	0.61	0.18	0.05	0.16	0.33	0.22	0.1	0.19		0.06
Common Stock	0.65	0.19	-0.01	0.42	0.77	-0.39	-0.93	-0.53	0.39	-0.07	0.57	0.08	0.86	0.83	0.86	0.91	0.59	0.72	0.65	-0.48	0.54	0.22	-0.59	0.06	0.06

Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Total Current Liabilities	12.9M	2.7M	2.7M	3.9M	4.2M	3.9M
Total Stockholder Equity	(107.9K)	24.8M	36.1M	26.5M	27.6M	17.8M
Property Plant And Equipment Net	727.5K	609.1K	976.3K	652K	647K	460.6K
Net Debt	(13.6M)	(30.8M)	(40.6M)	(11.3M)	(31.1M)	(29.6M)
Retained Earnings	(344.6M)	(367.1M)	(393.4M)	(418.3M)	(446.0M)	(423.7M)
Accounts Payable	3.2M	1.8K	594K	2.3M	1.1M	1.0M
Cash	14.1M	31.2M	41.3M	11.7M	31.5M	19.3M
Non Current Assets Total	727.5K	609.1K	976.3K	1.7M	647.0K	614.6K
Cash And Short Term Investments	14.1M	31.2M	41.3M	32.1M	34.9M	26.6M
Net Receivables	2.1M	89.7K	866.1K	521K	15K	14.3K
Common Stock Shares Outstanding	22.1M	40.3M	53.5M	58.0M	67.6M	71.0M
Liabilities And Stockholders Equity	19.7M	34.3M	45.9M	37.3M	38.8M	30.5M
Non Current Liabilities Total	6.9M	6.9M	7.1M	6.9M	7.0M	7.4M
Other Current Assets	1.5M	2.4M	2.8M	3.0M	3.2M	3.4M
Other Stockholder Equity	33.0M	34.6M	37.8M	40.1M	42.1M	38.1M
Total Liab	19.8M	9.6M	9.8M	10.8M	11.3M	6.0M
Property Plant And Equipment Gross	727.5K	609.1K	976.3K	652K	1.3M	1.4M
Total Current Assets	18.9M	33.7M	44.9M	35.7M	38.2M	28.0M
Accumulated Other Comprehensive Income	464.1K	400.2K	387.7K	662K	544K	516.8K
Short Term Investments	13.1M	30.4M	1.4M	20.5M	3.4M	3.2M
Short Term Debt	339.8K	248.9K	293.7K	216K	133K	126.4K
Other Current Liab	12.5M	2.5M	2.4M	1.5M	4.1M	2.8M
Common Stock	311.1M	356.8M	391.3M	404.0M	430.9M	310.7M
Common Stock Total Equity	271.7M	285.2M	311.1M	356.8M	410.3M	294.9M
Net Tangible Assets	(107.9K)	24.8M	36.1M	26.5M	30.5M	19.0M
Property Plant Equipment	727.5K	609.1K	976.3K	652K	749.8K	610.4K
Capital Surpluse	33.0M	34.6M	37.8M	40.1M	46.1M	35.9M
Long Term Debt Total	166.4K	153.2K	361.1K	157K	180.6K	131.6K
Cash And Equivalents	1.1M	858.0K	1.4M	11.7M	13.4M	14.1M
Current Deferred Revenue	(3.2K)	(1.8K)	(594K)	(1.1M)	(973.8K)	(925.1K)
Net Invested Capital	(107.9K)	24.8M	36.1M	26.5M	27.6M	20.3M
Net Working Capital	6.1M	31.0M	42.2M	31.7M	33.9M	26.6M
Capital Stock	311.1M	356.8M	391.3M	404.0M	430.9M	399.6M

Pair Trading with Oncolytics Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.

The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Oncolytics Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncolytics Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncolytics Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncolytics Biotech Stock:

How To Invest In Oncolytics

Details

Is Oncolytics Stock a good investment?

Details

What is Oncolytics Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncolytics Non Currrent Assets Other vs Cash Analysis

Non Currrent Assets Other vs Cash

Non Currrent Assets Other vs Cash Correlation Analysis

Correlation Coefficient

Non Currrent Assets Other

Cash

Oncolytics Biotech fundamental ratios Correlations

Oncolytics Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncolytics Biotech fundamental ratios Accounts

Pair Trading with Oncolytics Biotech

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Other Current Assets	+ 0.98	Common Stock Shares Outstanding
Short Term Debt	+ 0.97	Intangible Assets
Cash And Short Term Investments	+ 0.94	Total Stockholder Equity

Other Stockholder Equity	- 0.99	Retained Earnings
Cash	- 0.97	Net Debt
Common Stock	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.87	Net Debt
Total Current Assets	- 0.85	Net Debt
Short Term Debt	- 0.84	Other Stockholder Equity